CU20200042A7 - Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina - Google Patents

Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina

Info

Publication number
CU20200042A7
CU20200042A7 CU2020000042A CU20200042A CU20200042A7 CU 20200042 A7 CU20200042 A7 CU 20200042A7 CU 2020000042 A CU2020000042 A CU 2020000042A CU 20200042 A CU20200042 A CU 20200042A CU 20200042 A7 CU20200042 A7 CU 20200042A7
Authority
CU
Cuba
Prior art keywords
transtirretin
monoclonal antibody
antibody against
lyophilized formulation
lyophilized
Prior art date
Application number
CU2020000042A
Other languages
English (en)
Inventor
Andrea Hawe
Stefan Heindl
Jay Soto
Ruedeeporn Tantipolphan
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of CU20200042A7 publication Critical patent/CU20200042A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>La invención proporciona formulaciones de anticuerpo y métodos útiles para la profilaxis o el tratamiento de la amiloidosis mediada por transtirretina.</p>
CU2020000042A 2017-11-29 2018-11-28 Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina CU20200042A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762592294P 2017-11-29 2017-11-29
PCT/US2018/062902 WO2019108689A1 (en) 2017-11-29 2018-11-28 Lyophilized formulation of a monoclonal antibody against transthyretin

Publications (1)

Publication Number Publication Date
CU20200042A7 true CU20200042A7 (es) 2021-03-11

Family

ID=66665773

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000042A CU20200042A7 (es) 2017-11-29 2018-11-28 Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina

Country Status (19)

Country Link
US (1) US11873332B2 (es)
EP (1) EP3717512A4 (es)
JP (1) JP7337057B2 (es)
KR (1) KR20200090164A (es)
CN (1) CN111433223B (es)
AU (1) AU2018375356A1 (es)
BR (1) BR112020010483A2 (es)
CA (1) CA3083356A1 (es)
CL (1) CL2020001391A1 (es)
CU (1) CU20200042A7 (es)
EA (1) EA202091130A1 (es)
IL (1) IL274958A (es)
JO (1) JOP20200132A1 (es)
MA (1) MA51223A (es)
MX (1) MX2020005433A (es)
PE (1) PE20211453A1 (es)
PH (1) PH12020550694A1 (es)
SG (1) SG11202004187UA (es)
WO (1) WO2019108689A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
MX2020003041A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Anticuerpos anti-transtiretina.
WO2019071206A1 (en) 2017-10-06 2019-04-11 Prothena Biosciences Limited METHODS OF DETECTING TRANSTHYRETIN
MX2020005433A (es) 2017-11-29 2020-08-27 Prothena Biosciences Ltd Formulacion liofilizada de un anticuerpo monoclonal contra la transtirretina.
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
MX2022014223A (es) * 2020-05-12 2023-04-14 Neurimmune Ag Terapia de combinacion para amiloidosis de la ttr.
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
JP2023548005A (ja) * 2020-10-28 2023-11-15 ノヴォ ノルディスク アー／エス 抗トランスサイレチン抗体およびその使用方法
CN113845593B (zh) * 2021-10-27 2023-03-10 福州迈新生物技术开发有限公司 抗α-SMA蛋白单克隆抗体、细胞系及其应用
CA3239708A1 (en) 2021-12-03 2023-06-08 Aubin MICHALON Novel potency assay for antibody-based drugs and useful means therefor
EP4619431A1 (en) 2022-11-15 2025-09-24 Neurimmune AG Methods for treating or preventing transthyretin-mediated amyloidosis
JP2025537803A (ja) 2022-11-15 2025-11-20 ニューリミューン アーゲー トランスサイレチン媒介性アミロイドーシスを治療又は予防するための医薬組成物
WO2024123791A1 (en) * 2022-12-05 2024-06-13 Kodiak Sciences Inc. Formulations for dual vegf/il-6 inhibitors
EP4713354A1 (en) 2023-05-19 2026-03-25 Neurimmune AG Novel immunotherapy for musculoskeletal disorders and conditions
WO2025104243A1 (en) * 2023-11-15 2025-05-22 Neurimmune Ag Anti-transthyretin antibody, compositions comprising said antibody and methods for treating or preventing transthyretin-mediated amyloidosis
WO2025125544A1 (en) 2023-12-15 2025-06-19 Novo Nordisk A/S Stable liquid formulations
WO2025238147A1 (en) 2024-05-15 2025-11-20 Neurimmune Ag Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
MXPA01007845A (es) 1999-02-05 2004-06-22 Samsung Electronics Co Ltd Metodo para la recuperacion de la textura de imagenes y aparato para el mismo.
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2001077167A2 (en) 2000-04-05 2001-10-18 University Of Tennessee Research Corporation Methods of investigating, diagnosing, and treating amyloidosis
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
DE60336848D1 (de) 2002-09-12 2011-06-01 Univ California Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz
US20110200609A1 (en) 2002-09-12 2011-08-18 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence
US9535076B2 (en) 2002-09-12 2017-01-03 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
WO2010012004A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
JP4344325B2 (ja) 2002-11-29 2009-10-14 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なネオマイシンホスホトランスフェラーゼ遺伝子及び高生産組換え細胞の選抜方法
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
AU2004272112A1 (en) 2003-09-12 2005-03-24 The Regents Of The University Of California Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
CA2578400C (en) 2004-11-10 2014-01-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
WO2006108234A1 (en) 2005-04-13 2006-10-19 Garvan Institute Of Medical Research Modified animal lacking functional pyy gene, monoclonal antibodies that bind pyy isoforms and uses therefor
CA2642848C (en) 2006-03-03 2016-07-12 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-sod1 mediated diseases
US8232066B2 (en) 2006-07-03 2012-07-31 The Johns Hopkins University Peptide antibody depletion and its application to mass spectrometry sample preparation
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
EP2548647B1 (en) 2006-10-20 2018-08-15 CLONDIAG GmbH Assay devices and methods for the detection of analytes
SI2126093T1 (sl) 2007-03-02 2013-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Izboljšanje priprave proteinov
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
WO2010030203A1 (en) 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
US20100233176A1 (en) 2008-10-06 2010-09-16 Cashman Neil R Methods and systems for predicting misfolded protein epitopes
JP2010195710A (ja) 2009-02-25 2010-09-09 Kumamoto Univ アミロイド線維形成抑制剤及びその利用
EP2403871A4 (en) 2009-03-02 2013-01-16 Univ British Columbia FOR ABUSED PRION PROTEIN SPECIFIC ANTIBODIES AND EPITOPES
WO2011116123A1 (en) 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
ES2526522T3 (es) 2010-04-21 2015-01-13 Chiesi Farmaceutici S.P.A. Derivados del ácido 1-(2-fluorobifenil-4-il)alquil carboxílico para la terapia de la amiloidosis transtiretina
ES2625689T3 (es) 2010-04-29 2017-07-20 Ionis Pharmaceuticals, Inc. Modulación de la expresión de transtiretina
FI20115165A0 (fi) 2011-02-21 2011-02-21 Polysackaridforskning I Uppsala Ab Terapeuttisia ja diagnostisia menetelmiä
EP3604330A1 (en) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
EP2698431B1 (en) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP3892638A1 (en) 2012-05-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US9534048B2 (en) 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP2953970A4 (en) 2013-02-08 2016-06-29 Misfolding Diagnostics Inc TRANSTYRETIN ANTIBODIES AND USES THEREOF
WO2014142334A1 (ja) 2013-03-12 2014-09-18 国立大学法人名古屋大学 植物の光合成および生産量を増加させる方法
US20160168235A1 (en) 2013-07-19 2016-06-16 Board Of Regents Of The University Of Texas System Transthyretin amyloid-selective and polyreactive catabodies
WO2015092077A1 (en) 2013-12-20 2015-06-25 Neurimmune Holding Ag Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor
JP6517156B2 (ja) 2014-01-29 2019-05-22 Ｋｍバイオロジクス株式会社 抗トランスサイレチンヒト抗体
JP6818268B2 (ja) 2014-01-29 2021-01-20 Ｋｍバイオロジクス株式会社 抗トランスサイレチンヒト化抗体
LT3185957T (lt) 2014-08-29 2022-09-26 Alnylam Pharmaceuticals, Inc. Patisiranas, skirtas naudoti transtiretino amiloidozei gydyti
TWI761959B (zh) 2014-11-07 2022-04-21 瑞士商諾華公司 治療眼部疾病之方法
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI786505B (zh) * 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI769570B (zh) * 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478716A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478715A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7076711B2 (ja) 2016-07-02 2022-05-30 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
CN107389956B (zh) * 2017-08-31 2019-05-07 北京臻惠康生物科技有限公司 甲状腺素运载蛋白作为tbi患者受伤严重程度评估的新用途及其试剂盒
WO2019071206A1 (en) 2017-10-06 2019-04-11 Prothena Biosciences Limited METHODS OF DETECTING TRANSTHYRETIN
MX2020003041A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Anticuerpos anti-transtiretina.
MX2020005433A (es) 2017-11-29 2020-08-27 Prothena Biosciences Ltd Formulacion liofilizada de un anticuerpo monoclonal contra la transtirretina.
WO2021168156A1 (en) 2020-02-20 2021-08-26 Prothena Biosciences Limited Monitoring transthyretin amyloidosis

Also Published As

Publication number Publication date
IL274958A (en) 2020-07-30
KR20200090164A (ko) 2020-07-28
JP7337057B2 (ja) 2023-09-01
SG11202004187UA (en) 2020-06-29
EP3717512A1 (en) 2020-10-07
AU2018375356A1 (en) 2020-05-14
PH12020550694A1 (en) 2021-04-12
MA51223A (fr) 2020-10-07
JOP20200132A1 (ar) 2022-10-30
US20200362023A1 (en) 2020-11-19
WO2019108689A1 (en) 2019-06-06
CL2020001391A1 (es) 2020-11-13
CN111433223B (zh) 2024-08-27
JP2021504372A (ja) 2021-02-15
MX2020005433A (es) 2020-08-27
CA3083356A1 (en) 2019-06-06
US11873332B2 (en) 2024-01-16
CN111433223A (zh) 2020-07-17
BR112020010483A2 (pt) 2020-10-20
EA202091130A1 (ru) 2020-08-28
EP3717512A4 (en) 2021-08-25
PE20211453A1 (es) 2021-08-05

Similar Documents

Publication Publication Date Title
CU20200042A7 (es) Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina
CL2019003144A1 (es) Formulaciones de anticuerpos anti-lag3 y co-formulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
CY1125136T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1125659T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1124013T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
CO2018010459A2 (es) Composiciones que comprenden cepas bacterianas
CL2019001411A1 (es) Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817)
CL2018001349A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001367A1 (es) Composiciones que comprenden cepas bacterianas
SV2018005614A (es) Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias
CL2022000531A1 (es) Composiciones y métodos para el tratamiento de infecciones virales.
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CO2019014647A2 (es) Composiciones inmunogénicas
ECSP19090645A (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta
CY1124286T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CL2023003695A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
CL2018000317A1 (es) Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
MX392976B (es) Composiciones que comprenden cepas bacterianas.